Rock Creek Pharmaceuticals Inc (fka RCPIQ)

[NukeJohn]

January 2014 should be a good month for Rock Creek Pharmaceuticals.

Here are just a few reasons I think we are at or near a bottom.

1. The tax loss sellers are done, and many of those sold in late Nov or early Dec (so they could buy back in early Jan and avoid the wash sale rule). Those buying back should exert upward pressure on the stock.

2. Many of the technicals are turning upwards such as the MACD, Full Stochastics, True Strength Index (TSI), TRIX, Williams %R, Know Sure Thing (KST), etc. If you are interested, go to stockcharts.com, enter STSI and then enter some of the indicators listed above.

3. The company now has new management with successful backgrounds in Alzheimer's Disease trials and getting drugs through the FDA approval process. They appear to be ready to hit the ground running with upcoming investment conferences and discussions with Pharmas.

4. Word is spreading about Anatabloc and autoimmune-related diseases with numerous testimonials on dozens of web sites. While it doesn't help everyone, the success rate appears to be about 75-80% with virtually no side effects. I suspect many who did not show improvement weren't taking enough or weren't taking it throughout the day. There are testimonials on everything from MS to AD, from RA to Diabetes, from Crohn's Diseases and IBS to endometriosis, from some types of cancer to allergies, from asthma to eyesight improvement, from rosacia to eczema and psoriasis....and the list goes on and on.

5. Big Pharmas appreciate the significance of a drug that could help regulate transcription of NF-kB and control inflammation in the body. For example, Abbott paid $400 million two years ago for a chance to partner with Riata Pharmaceuticals for bardoxolone methyl, but later that drug had safety concerns in the phase 3 trials (see link below).

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94362068

6. Rock Creek has announced plans to pursue FDA drug approval "with a vengeance" (according to quote from the ASM).

7. Patrick Cox has recently stated he is more convinced than ever about Anatabine being a breakthrough medical discovery and he will start covering it again in early 2014. Now that he is associated with John Mauldin, tens of thousands of new potential investors will be learning about Anatabine and Rock Creek Pharmaceuticals.


Turn Back The Clock With Anatabloc.

JMHO,

NJ